- Home
- CX vs EXEL Comparison
CX vs EXEL Comparison
Compare CX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CX
- EXEL
- Stock Information
- Founded
- CX 1906
- EXEL 1994
- Country
- CX Mexico
- EXEL United States
- Employees
- CX N/A
- EXEL N/A
- Industry
- CX Building Materials
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CX Industrials
- EXEL Health Care
- Exchange
- CX Nasdaq
- EXEL Nasdaq
- Market Cap
- CX 8.5B
- EXEL 10.0B
- IPO Year
- CX 1999
- EXEL 2000
- Fundamental
- Price
- CX $5.64
- EXEL $33.29
- Analyst Decision
- CX Buy
- EXEL Buy
- Analyst Count
- CX 6
- EXEL 16
- Target Price
- CX $7.70
- EXEL $32.75
- AVG Volume (30 Days)
- CX 10.1M
- EXEL 2.1M
- Earning Date
- CX 02-06-2025
- EXEL 02-04-2025
- Dividend Yield
- CX 0.74%
- EXEL N/A
- EPS Growth
- CX N/A
- EXEL 441.02
- EPS
- CX 0.02
- EXEL 1.55
- Revenue
- CX $17,249,067,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- CX $5.48
- EXEL $20.59
- Revenue Next Year
- CX $3.14
- EXEL $1.50
- P/E Ratio
- CX $18.13
- EXEL $21.51
- Revenue Growth
- CX 5.20
- EXEL 17.31
- 52 Week Low
- CX $5.00
- EXEL $19.20
- 52 Week High
- CX $9.27
- EXEL $36.97
- Technical
- Relative Strength Index (RSI)
- CX 50.48
- EXEL 40.46
- Support Level
- CX $5.50
- EXEL $34.58
- Resistance Level
- CX $5.64
- EXEL $36.22
- Average True Range (ATR)
- CX 0.16
- EXEL 0.80
- MACD
- CX -0.00
- EXEL -0.44
- Stochastic Oscillator
- CX 40.82
- EXEL 5.79
About CX Cemex S.A.B. de C.V. Sponsored ADR
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and services.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.